期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 11, 期 17, 页码 2879-2889出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2010.509344
关键词
menstrual disorders; oral contraceptives; PMS; premenstrual syndrome; serotonin reuptake inhibitors; treatment
资金
- Forest Research
- Wyeth
- Pfizer
- Xanodyne Pharmaceuticals
- Eli Lilly
- GlaxoSmithKline
- Warner-Lambert
- Berlex
- Solvay Pharmaceuticals
Importance of the field: Premenstrual syndrome (PMS) is among the most common health problems reported by reproductive-age women. Estimates indicate that up to 25% of women may warrant treatment for the distress or impaired functioning associated with the symptoms. Areas covered in this review: The primary focus of this review is the clinical condition of PMS and randomized, placebo-controlled trials of PMS treatment. A literature search in PubMed was conducted for these topics. The most recent reports of specific treatments in controlled treatment studies and all meta-analyses were selected. What the reader will gain: Reports consistently indicate that serotonergic antidepressants reduce PMS symptoms compared to a placebo. Hormonal treatments are the most widely prescribed medical treatment. Some oral contraceptives and gonadotropin-releasing hormone analogs have demonstrated efficacy, particularly for women who want contraception and PMS symptom control. Numerous non-pharmacologic treatments are utilized, but efficacy is reported only for calcium supplements, Vitex agnus castus (chasteberry), and cognitive-behavioral therapies. Further research to develop new therapies for the 40% of women with PMS who do not respond to the currently available treatments is needed. Take home message: There are treatments with demonstrated efficacy for PMS, and the majority of women can be helped.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据